These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28693210)

  • 21. Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review.
    Chen S; He Y; Liu J; Chen X; Yu J; Li W; Chen B; Sun C; Zhou C
    Onco Targets Ther; 2019; 12():11305-11311. PubMed ID: 31908495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer.
    Sonoda T; Nishikawa S; Sakakibara R; Saiki M; Ariyasu R; Koyama J; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ninomiya H; Ishikawa Y; Nishio M
    Respir Med Case Rep; 2018; 24():19-21. PubMed ID: 29977749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report.
    Lee S; Joo J; Kwak M; Sohn K; Chon S
    Onco Targets Ther; 2018; 11():3943-3947. PubMed ID: 30022837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor.
    Kim WJ; Kim S; Choi H; Chang J; Shin HJ; Park CK; Oh IJ; Kim KS; Kim YC; Choi YD
    Thorac Cancer; 2015 Nov; 6(6):800-4. PubMed ID: 26557922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases.
    Ahn S; Hwang SH; Han J; Choi YL; Lee SH; Ahn JS; Park K; Ahn MJ; Park WY
    J Pathol Transl Med; 2016 Jul; 50(4):258-63. PubMed ID: 27160687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes in Patients With Lung Adenocarcinoma With Transformation to Small Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitors Resistance: A Systematic Review and Pooled Analysis.
    Xu J; Xu L; Wang B; Kong W; Chen Y; Yu Z
    Front Oncol; 2021; 11():766148. PubMed ID: 35223450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic and molecular characteristics of
    Yu L; Bazhenova L; Gold K; Tran L; Hilburn V; Vu P; Patel SP
    Transl Lung Cancer Res; 2022 Mar; 11(3):452-461. PubMed ID: 35399568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report.
    Kok VC; Lee CK; Chiang YH; Wang MC; Lu YT; Cherng CC; Lee PY; Wang KB
    Front Oncol; 2021; 11():564799. PubMed ID: 33816221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
    Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T
    Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases.
    Jin CB; Yang L
    World J Clin Cases; 2021 Jun; 9(18):4617-4626. PubMed ID: 34222428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advanced Lung Adenocarcinoma with EGFR 19-del Mutation Transformed into SCC after EGFR-tyrosine Kinase inhibitors Treatment: A Case report.
    Ji XZ; Liu ZD; Ye YP; Li Q; Liu XJ; Zhou MH; Jin Y
    World J Clin Cases; 2024 Jul; 12(20):4405-4411. PubMed ID: 39015891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma.
    Zhai X; Liu J; Liang Z; Li Z; Liu Y; Huang L; Wang W; Luo F
    Front Oncol; 2021; 11():661034. PubMed ID: 34249697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and molecular profiling of EGFR-mutant lung adenocarcinomas transformation to small cell lung cancer during TKI treatment.
    Chen Y; He M; Dai Z; Wang Y; Chen J; Wang X; Dong X; Huang J; Ruan J; Zhang X; Shen P; Jia Y
    Front Oncol; 2023; 13():1308313. PubMed ID: 38188289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transformation From Adenocarcinoma to Pleomorphic Carcinoma as an Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Nishimatsu K; Minami S; Ihara S; Yasuoka H
    J Med Cases; 2021 Aug; 12(8):310-314. PubMed ID: 34434479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations.
    Suh KJ; Keam B; Kim M; Park YS; Kim TM; Jeon YK; Kim DW; Chung DH; Kim YW; Heo DS
    Clin Lung Cancer; 2016 Jul; 17(4):245-252.e1. PubMed ID: 26719155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
    Mambetsariev I; Arvanitis L; Fricke J; Pharaon R; Baroz AR; Afkhami M; Koczywas M; Massarelli E; Salgia R
    J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells.
    Tenjin Y; Nakamura K; Ishizuka S; Saruwatari K; Sato R; Tomita Y; Saeki S; Ichiyasu H; Fujii K; Ito T; Sakagami T
    Intern Med; 2019 Nov; 58(22):3261-3265. PubMed ID: 31292388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance.
    Xu S; Liu X; Liu R; Shi T; Li X; Zhong D; Wang Y; Chen G; Chen J
    Thorac Cancer; 2017 Nov; 8(6):693-697. PubMed ID: 28786540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.